Systemic Lupus Erthematosus Clinical Trials

7 recruiting

Systemic Lupus Erthematosus Trials at a Glance

12 actively recruiting trials for systemic lupus erthematosus are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Hangzhou, Bethesda, and Bonn. Lead sponsors running systemic lupus erthematosus studies include The Children's Hospital of Zhejiang University School of Medicine, Hinge Bio, and Genrix (Shanghai) Biopharmaceutical Co., Ltd..

Browse systemic lupus erthematosus trials by phase

Treatments under study

About Systemic Lupus Erthematosus Clinical Trials

Looking for clinical trials for Systemic Lupus Erthematosus? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Lupus Erthematosus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Lupus Erthematosus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

VasculitisSystemic Lupus Erthematosus (SLE)Rheumatic Diseases+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled1 locationNCT07278609
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Lupus Nephritis (LN)Systemic Lupus Erthematosus (SLE)Extra-renal Lupus (ERL)
Hinge Bio30 enrolled1 locationNCT07491900
Recruiting
Phase 1Phase 2

A Study of GR1803 in Systemic Lupus Erythematosus

Systemic Lupus ErthematosusAuto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd.44 enrolled1 locationNCT07348055
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Early Phase 1

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic Syndrome+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT06792799
Recruiting
Phase 1

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

Systemic Lupus ErythematosusSLESystemic Lupus Erythematosus (SLE)+2 more
LiveKidney.Bio10 enrolled1 locationNCT06737380
Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+10 more
University of Bonn120 enrolled1 locationNCT07150000
Recruiting
Phase 1Phase 2

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
Peking University Third Hospital9 enrolled1 locationNCT06828042
Recruiting
Phase 1

Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erthematosus
Biocad135 enrolled1 locationNCT07136389
Recruiting

Rare AutoImmune SElf-management Programme Development

Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
University of the West of England360 enrolled1 locationNCT06642870